

Science Behind TRU NIAGEN® to be Featured at the World Mitochondria Society Meeting

2018-10-22

Frank Jaksch to speak on healthy aging and the research supporting TRU NIAGEN® in Berlin

LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it will present the science behind TRU NIAGEN® (nicotinamide riboside) at the 9th World Congress on Targeting Mitochondria 2018 in Berlin, Germany, from Oct. 23-25.

Frank Jaksch, ChromaDex Co-Founder & Executive Chairman, will present “The Nicotinamide Riboside Journey, From Discovery To Clinical Efficacy” to the World Mitochondria Society to review the biochemical and physiological role of nicotinamide adenine dinucleotide (NAD) with an emphasis on the implications these processes have on healthy aging.

“I am very grateful for the opportunity to speak at the World Mitochondria Society meeting this year,” says Jaksch. “I look forward to sharing the science behind our revolutionary ingredient with mitochondrial researchers from around the world.”

Additional highlights of the conference will include how to target and manipulate mitochondrial function in order to develop future mitochondria-based therapies, nutritional and pharmaceutical interventions for mitochondrial respiratory deficiencies, and the role of mitochondria in the process of aging.

“The future of medicine lies with mitochondria,” says Volkmar Weissig, PhD, President of the World Mitochondria Society. “We are excited to learn more about the role of NAD in future research.”

For additional information on the science supporting TRU NIAGEN visit www.truniagen.com.

About ChromaDex:

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, **NIAGEN**[®] nicotinamide riboside, sold directly to consumers as **TRU NIAGEN**[®], is backed with clinical and scientific research, as well as extensive IP protection. **TRU NIAGEN**[®] is helping the world AGE BETTER[®]. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

About TRU NIAGEN[®]:

TRU NIAGEN[®] is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN[®] nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN[®]. Multiple clinical trials demonstrate NIAGEN[®] is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN[®] has twice been successfully reviewed under FDA's new dietary ingredient ("NDI") notification program, and has also been successfully notified to the FDA as generally recognized as safe ("GRAS").

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.

ChromaDex Media Contact:

Alex Worsham, Director of Strategic Partnerships
949-648-3775

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Sr. Director of FP&A and Investor Relations

949-600-9727

briannag@chromadex.com

ChromaDex Corporation